Cabaletta Bio Inc (CABA)
7.255
-1.10
(-13.22%)
USD |
NASDAQ |
Jun 25, 16:00
7.255
0.00 (0.00%)
After-Hours: 18:50
Cabaletta Bio Research and Development Expense (Annual): 55.42M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 55.42M |
| December 31, 2022 | 39.30M |
| December 31, 2021 | 32.49M |
| Date | Value |
|---|---|
| December 31, 2020 | 21.38M |
| December 31, 2019 | 11.67M |
| December 31, 2018 | 4.467M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
11.67M
Minimum
2019
55.42M
Maximum
2023
32.05M
Average
32.49M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Editas Medicine Inc | 177.65M |
| ACADIA Pharmaceuticals Inc | 351.62M |
| Alnylam Pharmaceuticals Inc | 1.004B |
| Regeneron Pharmaceuticals Inc | 4.439B |
| Vertex Pharmaceuticals Inc | 3.163B |